Picture of Bristol-Myers Squibb logo

CELG RT — Bristol-Myers Squibb News Story

0.000.00%
us flag iconLast trade - 00:00
HealthcareHighly SpeculativeLarge CapSuper Stock

Bristol Myers to merge scientific, clinical teams under new R&D structure

Bristol Myers to merge scientific, clinical teams under new R&D structure

- Bristol Myers Squibb BMY.N said on Thursday it will combine its scientific and clinical expertise teams into an end-to-end research and development department under current Chief Medical Officer Cristian Massacesi, effective January 1, 2027.

Current Chief Research Officer Robert Plenge will leave in March 2027 after the transition.

  • "Bringing Research and Development together as one organization is an important step in our work to position BMS for long-term growth," said CEO Christopher Boerner

  • Analysts are closely watching Bristol's drug development pipeline for clues on growth

  • "Under Cristian's leadership, this new structure will more closely connect our scientific and clinical expertise across R&D, accelerate decision making and ultimately enhance portfolio execution," Boerner said


(Reporting by Sneha S K in Bengaluru)

((Sneha.SK@thomsonreuters.com;))

Recent news on Bristol-Myers Squibb

See all news